Cybin Begins Phase 3 Depression Trials Enrolling 550 Patients

Cybin Inc., a clinical-stage neuropsychiatry company, has begun patient dosing in its Phase 3 CYB003 PARADIGM program targeting Major Depressive Disorder, involving approximately 550 participants across three studies. The company has strengthened its commercialization and manufacturing capabilities through partnerships with Thermo Fisher Scientific and Osmind, while also expanding its intellectual property portfolio with patents protecting its lead programs until 2040-2041. CEO Doug Drysdale highlighted positive regulatory signals from U.S. agencies that could expedite approval pathways for Cybin’s clinical programs, reflecting growing support for psychedelic therapeutics. Drysdale is also scheduled to participate in a panel discussion at the Psychedelic Science 2025 Conference, emphasizing the company’s commitment to advancing innovative mental health treatments. Despite ongoing financial challenges such as lack of revenue and continuous losses, Cybin’s clinical progress and strategic initiatives indicate potential for future growth in addressing unmet mental health needs. The company is also advancing CYB004, a deuterated DMT compound in Phase 2 trials for generalized anxiety disorder.